Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.19 USD
Change Today -0.23 / -16.20%
Volume 1.4M
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$1.30
Previous Close
$1.42
Day High
$1.32
Day Low
$1.13
52 Week High
06/23/14 - $3.00
52 Week Low
05/8/15 - $0.80
Market Cap
14.5M
Average Volume 10 Days
1.3M
EPS TTM
$-1.35
Shares Outstanding
12.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarncinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

25 Employees
Last Reported Date: 03/11/15
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $401.3K
Executive Chairman
Total Annual Compensation: $40.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $233.1K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $284.3K
Compensation as of Fiscal Year 2014.

delcath systems inc (DCTH) Key Developments

Delcath Systems, Inc. Names Dr. Jennifer Simpson as its President and Chief Executive Officer

Delcath Systems, Inc. announced that Jennifer Simpson, Ph.D., M.S.N., C.R.N.P. has been named President and Chief Executive Officer by the company's Board of Directors, effective immediately. Dr. Simpson has served as Interim President and Chief Executive Officer of Delcath since September 2014 and as Interim Co-President and Co-Chief Executive Officer from September 2013 to September 2014. She joined Delcath in 2012 as Executive Vice President, Global Marketing. Prior to joining Delcath. Dr. Simpson was Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc. Dr. Simpson served as Vice President, Product Champion and from 2008 to 2009 as Associate Vice President, Product Champion for a late-stage asset at ImClone.

Delcath Systems, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Delcath Systems, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $444,000 compared to $310,000 a year ago. Operating loss was $3,708,000 compared to $5,059,000 a year ago. Net loss was $3,488,000 compared to $5,278,000 a year ago. Basic and diluted loss per share was $0.32 compared to $0.57 a year ago. Cash and cash equivalents as of March 31, 2015 were $18.5 million, compared with $20.5 million as of December 31, 2014. During the first quarter of 2015, net cash used in operating activities was $4.4 million.

Delcath Adds New U.S. Center to Global Phase 2 Hepatocellular Carcinoma Program

Delcath Systems, Inc. announced the expansion of its global Phase 2 program for the treatment of patients with unrespectable hepatocellular carcinoma (HCC) or primary liver cancer. Montefiore Medical Center in the Bronx, New York has joined the U.S. Phase 2 HCC study and is now open for patient enrollment. The Company now has two centers participating in the U.S. Phase 2 HCC study, with another three centers in Gerany enrolling patients in the EU Phase 2 HCC study. The Company expects to include up to seven centers in Europe and the United States in its global Phase 2 HCC program, and will seek to enroll approximately 30 patients in total.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $1.19 USD -0.23

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $16.15 USD +0.10
CTI BioPharma Corp $1.90 USD +0.15
Curis Inc $3.25 USD +0.05
Exact Sciences Corp $27.13 USD -0.18
Sirtex Medical Ltd A$26.68 AUD 0.00
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.